• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

146062-49-9 (MSDC 0160)

1

Identification

MSDC 0160 MSDC 0160
Name MSDC 0160
Formula C19H18N2O4S
MW 370.42
CAS No. 146062-49-9
EINECS
Smiles O=C(N1)SC(CC2=CC=C(OCC(C3=NC=C(CC)C=C3)=O)C=C2)C1=O
Synonyms MSDC-0160;MSDC0160;Mitoglitazone;CAY 10415;CAY-10415;CAY10415; 5-(4-(2-(5-ethylpyridin-2-yl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione
InChI InChI=1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24)
2

Introduction

MSDC-0160 is a prototype mTOT-modulating insulin sensitizer being studied to treat diabetes and Alzheimer's disease. Phase 2.

Background Information

MSDC-0160 is a prototype mTOT-modulating insulin sensitizer being studied to treat diabetes and Alzheimer's disease. ......by AdooQ BioScience, LLC
MSDC-0160 reduces resistance in the insulin/IGF-1 signaling pathway and restores IGF-1-induced Akt and GSK-3 phosphorylation. ......by BOC Sciences
CAY-10415 is a potent anti-diabetic drug of the TZD structural class. CAY-10415 lowers blood glucose levels in obese, hyperglycemic, hyperinsulinemic, and insulin-resistant KKAγ mice. It enhances the rate of insulin-stimulated lipogenesis in 3T3-L1 adipocytes in a dose-dependent manner. ......by BioVision, Inc.,
CAY10415 is a novel peroxisome proliferator-activated receptor (PPAR)γ ligand. CAY10415 induced cell death and ROS generation in a PPARγ-independent manner. CAY10415 enhanced γ-radiation-induced apoptosis and caspase-3-mediated poly (ADP-ribose) polymerase (PARP) cleavage in vitro. The combined CAY10415 / γ-radiation treatment triggered caspase-8 activation, and this initiator caspase played an important role in the combination-induced apoptosis. The combined treatment of CAY10415 and γ-radiation synergistically induced DNA damage and apoptosis, which was regulated by ROS. ......by MedKoo Biosciences, Inc.
A new generation insulin sensitizer and mitochondrial target of thiazolidinediones (mTOT) modulator that has low affinity for binding and activation of PPARγ (EC50=23.7 uM) and shows insulin-sensitizing effects in mouse models of diabetes; increases AMPK activity and reduces mTOR activity, maintains β-cell phenotype in human islets.DiabetesPhase 2 Clinical ......by ProbeChem
MSDC-0160 is a prototype mTOT-modulating insulin sensitizer being studied to treat diabetes and Alzheimer's disease. Phase 2. ......by Selleck Chemicals LLC
Insulin sensitizer; enhances insulin sensitivity and lowers blood-glucose levels in diabetic mouse models. Inhibits mitochondria pyruvate carriers; increases mitochondrial respiration rates, leading to a reduction in expression of lipogenic enzymes. Suppresses gluconeogenesis and lipogenesis in primary hepatocytes. Exhibits low binding affinity and activity at PPARγ (EC50 = 23.7 μM). ......by Tocris Bioscience Inc.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000122499

Storage condition

Solubility

DMSO: ≥ 30 mg/mL by CHEMSCENE, LLC
DMSO: ≥ 30 mg/mL by MedChemexpress Co., Ltd.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
MSDC 0160 Metabolic Solutions Development Company Type 2 Diabetes 2010/9/1 Phase 2
MSDC 0160 Metabolic Solutions Development Company Alzheimer's Disease 2011/7/1 Phase 2
MSDC 0160 Metabolic Solutions Development Company Type 2 Diabetes Mellitus 2008/9/1 Phase 2
7

Safety Data of MSDC 0160

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AdooQ BioScience, LLC USA
Ark Pharm, Inc. USA
BOC Sciences
BioVision, Inc., USA
Biochempartner Co., Ltd China
CHEMSCENE, LLC 2mg/USD72();5mg/USD132() USA
Cayman Chemical Company USA
MedChemexpress Co., Ltd. 2mg/USD72();5mg/USD132() USA
MedKoo Biosciences, Inc. USA
ProbeChem
Selleck Chemicals LLC USA
Shanghai Haoyuan Chemexpress Co., Ltd. 2mg/USD72();5mg/USD132() China
Tocris Bioscience Inc. USA
10

Related Products

Other Forms of 146062-49-9

Name CAS No Formula MW

Recommended Compounds in Insulin Receptor

Name CAS No Formula MW
LDK378 (dihydrochloride) 1380575-43-8 C28H38Cl3N5O3S 631.06
LDK378 1032900-25-6 C28H36ClN5O3S 558.14
KU14R 189224-48-4 C13H14N2O 214.26
GSK1838705A 1116235-97-2 C27H29FN8O3 532.57
BMS-754807 1001350-96-4 C23H24FN9O 461.49
NVP-AEW541 475489-16-8 C27H29N5O 439.55
Linsitinib 867160-71-2 C26H23N5O 421.49
BMS-536924 468740-43-4 C25H26ClN5O3 479.96
NT157 1384426-12-3 C16H14BrNO5S 412.26

Recommended Compounds in Same Indication

Name CAS No Formula MW
Tofogliflozin 903565-83-3 C22H26O6 386.4382
ETC-1002 738606-46-7 C19H36O5 344.49
CHF5074 749269-83-8 C16H11Cl2FO2 325.1617
Azeliragon 603148-36-3 C32H38ClN3O2 532.116
LY451395 375345-95-2 C21H30N2O4S2 438.6
Tofogliflozin (hydrate) 1201913-82-7 C22H28O7 404.4535
Bromocriptine mesylate 22260-51-1 C33H44BrN5O8S 750.7
CCX140 1100318-47-5 C20H13ClF3N5O3S 495.86
LGD-6972 1207989-09-0 C43H46N2O5S 702.9
THK5351 1707147-26-9 C18H18FN3O2 0.0
Dutogliptin 852329-66-9 C10H20BN3O3 241.1
MK-0249 862309-06-6 C23H24F3N3O2 431.45
Heparin 9005-49-6 C26H42N2O37S5 1134.93
11

Route of Synthesis

12

References

13

More Information

MSDC 0160

Tags: buy 146062-49-9 IC50 | 146062-49-9 price | 146062-49-9 cost | 146062-49-9 solubility | 146062-49-9 purchase | 146062-49-9 manufacturer | 146062-49-9 research buy | 146062-49-9 order | 146062-49-9 MSDS | 146062-49-9 chemical structure | 146062-49-9 Storage condition | 146062-49-9 molecular weight | 146062-49-9 mw | 146062-49-9 datasheet | 146062-49-9 supplier | 146062-49-9 cell line | 146062-49-9 NMR | 146062-49-9 MS | 146062-49-9 IR | 146062-49-9 solubility | 146062-49-9 Safe information | 146062-49-9 Qc and Spectral Information | 146062-49-9 Clinical Information | 146062-49-9 Clinical Trial | 146062-49-9 Route of Synthesis | 146062-49-9 storage condition | 146062-49-9 diseases and conditions | 146062-49-9 flash point | 146062-49-9 boiling point | 146062-49-9 melting point | 146062-49-9 storage condition | 146062-49-9 brand